The future of phosphate binders: A perspective on novel therapeutics

Expert Opinion on Investigational Drugs

Volumn 23, Issue 11, 2014, Pages 1459-1463

  Cernaro, Valeria ^a   Santoro, Domenico ^a   Lucisano, Silvia ^a   Nicocia, Giacomo ^b   Lacquaniti, Antonio ^c   Buemi, Michele ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

Author keywords

Chronic kidney disease mineral bone disorder; Fibroblast growth factor 23; Phosphate; Phosphate binders; Vascular calcifications

Indexed keywords

BIOLOGICAL MARKER; BIXALOMER; CALCIMIMETIC AGENT; FERMAGATE; FERRIC HYDROXIDE ADIPATE; FIBROBLAST GROWTH FACTOR 23; GENZ 644470; KRX 0502; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SBR 759; SEVELAMER; SUCROFERRIC OXYHYDROXIDE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; CHELATING AGENT; FIBROBLAST GROWTH FACTOR;

BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE REMODELING; CHRONIC KIDNEY DISEASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; META ANALYSIS (TOPIC); MINERAL BONE DISORDER; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; REVIEW; ANIMAL; BLOOD; BONE DISEASES, METABOLIC; COMPLICATION; DRUG DESIGN; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; BIOLOGICAL MARKERS; BONE DISEASES, METABOLIC; CHELATING AGENTS; DRUG DESIGN; FIBROBLAST GROWTH FACTORS; HUMANS; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84911949193     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.962652     Document Type: Review

References (25)

1. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2006; 69(11): 1945-53
2. Kidney Disease: improving Global Outcomes (KDIGO) CKD - MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD - MBD). Kidney Int 2009; 76(Suppl 113): S1-S130
3. Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 2014; 10(5): 268-78
4. Locatelli F, Del Vecchio L, Violo L, Pontoriero G. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opin Drug Saf 2014; 13(5): 551-61
5. Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 54(4): 619-37
6. Locatelli F, Del Vecchio L. Optimal phosphate control: still an unmet need in chronic kidney disease patients. Expert Opin Pharmacother 2014; 15(3): 307-9
7. Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006; 21(8): 2217-24
8. Frazão JM, Adragão T. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects. Nephron Clin Pract 2012; 120(2): c108-19
9. Wu-Wong JR, Mizobuchi M. Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease? Expert Opin Investig Drugs 2014; 1-11, doi: 10.1517/13543784.2014.933808. Available from: http://clinicaltrials.gov/ct2/home
10. Hatakeyama S, Murasawa H, Narita T, et al. Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, nonrandomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis. BMC Nephrol 2013; 14: 222
11. Ito K, Takeshima A, Shishido K, et al. Treatment of hyperphosphatemia with bixalomer in Japanese patients on longterm hemodialysis with gastrointestinal symptoms. Ther Apher Dial 2014; 18(Suppl 2): 19-23
12. Gen S, Sasaki T, Saito K, et al. Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride. Ther Apher Dial 2014; 18(Suppl 2): 8-12
13. Savica V, Calò LA, Santoro D, et al. Salivary glands: a new player in phosphorus metabolism. J Ren Nutr 2011; 21(1): 39-42
14. Block GA, Persky MS, Shamblin BM, et al. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease. Nephron Clin Pract 2013; 123(1-2): 93-101
15. Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 2014; 86(3): 638-47
16. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90(3): 1519-24
17. Larsson T, Olauson H. [A brief update on FGF23 for the clinical nephrologist]. G Ital Nefrol 2014; 31(2). pii: gin/31.2.11
18. Crisafulli A, Romeo A, Floccari F, et al. Osteoprotegerin and bone mineral density in hemodiafiltration patients. Ren Fail 2005; 27(5): 531-9
19. Cernaro V, Lacquaniti A, Lupica R, et al. Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein. Med Res Rev 2014; 34(1): 77-105
20. Xu R. Semaphorin 3A: a new player in bone remodeling. Cell Adh Migr 2014; 8(1): 5-10
21. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23(8): 1407-15
22. Ureña-Torres P, Prie D, Keddad K, et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial. BMC Nephrol 2014; 15: 71
23. Nagano N, Miyata S, Abe M, et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006; 69(3): 531-7
24. Olauson H, Larsson TE. FGF23 and Klotho in chronic kidney disease. Curr Opin Nephrol Hypertens 2013; 22(4): 397-404
25. Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012; 122(7): 2543-53